Avacta Group Plc (AVCT) - Medical Equipment - Deals and Alliances Profile

Region:Europe

Author(s):

Product Code:GDME16609D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

December 2018

Total pages

56

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products that include optim and sensipod. It also develops UCB celltech that is an analytical instrument. Avacta's sensipod is an in-clinical blood testing system that delivers ELISA tests. The company offers intellectual property relating to an alternative to antibodies. It develops reagents and diagnostics that are used in affinity chromatography, protein to protein interactions, immunoassay and rapid diagnostic test applications, among others. It has operations in Wetherby, Cambridge and London. Avacta is headquartered in Wetherby, the UK.

Avacta Group Plc (AVCT)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Avacta Group Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Avacta Group Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5

Avacta Group Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6

Avacta Group Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7

Avacta Group Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8

Avacta Group Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9

Avacta Group Plc, Medical Equipment, Deal Details 10

Partnerships 10

New England Biolabs Enters into Licensing Agreement with Avacta 10

Two US biotech companies Enter into Licensing Agreement with Avacta 11

FIT Biotech Enters into Agreement with Avacta 12

Avacta Enters into Agreement with Mologic 13

Equity Offering 14

Avacta Group Raises USD15.2 Million in Private Placement of Shares 14

Avacta Group to Raise up to USD34.2 Million in Private Placement of Shares 15

Asset Transactions 16

Unchained Labs Acquires Optim Technology from Avacta for USD5 Million 16

Avacta Group Plc-Key Competitors 17

Avacta Group Plc-Key Employees 18

Avacta Group Plc-Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Recent Developments 21

Financial Announcements 21

Oct 02, 2018: Avacta Group: Preliminary results for the year ending 31 July 2018 21

Apr 16, 2018: Avacta Group Announces Interim Results for the Period Ended 31 January 2018 34

Oct 04, 2017: Avacta Group: Preliminary Results for the Year Ending 31 July 2017 40

Aug 07, 2017: Avacta Group: Trading Update and Notice of Results 41

Apr 03, 2017: Avacta Group: Interim results for the period ended 31 January 2017 43

Corporate Communications 44

Jun 11, 2018: Avacta Group Appointments Dr Eliot Forster As Non-Executive Chairman 44

Mar 29, 2018: Avacta Group Announces Directorate Change 45

Oct 02, 2017: Avacta Establishes US Business Development Team 46

Government and Public Interest 47

Jan 20, 2017: AGM business update and notice of results 47

Product News 48

Oct 11, 2018: Avacta's Chief Technology Officer to present at major US conference 48

Dec 10, 2017: Avacta to Present Customer Data at Major US Conference 49

Nov 15, 2017: Covance to Present Affimer Data at European Conference 50

May 10, 2017: Avacta Group: Key Affimer patent to be granted in China 51

May 10, 2017: Avacta: Key Affimer patent to be granted in China 52

Apr 03, 2017: Excellent results for Affimer technology in Industry-standard immunogenicity study using human samples 53

Other Significant Developments 54

Jan 18, 2018: Avacta Group: AGM Business Update and Notice of Results 54

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List of Figure

List of Figures

Avacta Group Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Avacta Group Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Avacta Group Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Avacta Group Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Avacta Group Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5

Avacta Group Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6

Avacta Group Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7

Avacta Group Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8


List of Table

List of Tables

Avacta Group Plc, Medical Equipment, Key Facts, 2018 2

Avacta Group Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Avacta Group Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5

Avacta Group Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6

Avacta Group Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7

Avacta Group Plc, Deals By Market, 2012 to YTD 2018 8

Avacta Group Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9

New England Biolabs Enters into Licensing Agreement with Avacta 10

Two US biotech companies Enter into Licensing Agreement with Avacta 11

FIT Biotech Enters into Agreement with Avacta 12

Avacta Enters into Agreement with Mologic 13

Avacta Group Raises USD15.2 Million in Private Placement of Shares 14

Avacta Group to Raise up to USD34.2 Million in Private Placement of Shares 15

Unchained Labs Acquires Optim Technology from Avacta for USD5 Million 16

Avacta Group Plc, Key Competitors 17

Avacta Group Plc, Key Employees 18

Avacta Group Plc, Other Locations 19

Avacta Group Plc, Subsidiaries 19

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022